We have hypothesized that the co-localization of digestive zymogens with lysosomal hydrolases, which occurs during the early stages of every experimental pancreatitis model, facilitates activation of those zymogens by lysosomal hydrolases such as cathepsin B and that this activation triggers acute pancreatitis by leading to acinar cell injury. Some, however, have argued that the co-localization phenomenon may be the result, rather than the cause, of zymogen activation during pancreatitis. To resolve this controversy and explore the causal relationships between zymogen activation and other early pancreatitis events, we induced pancreatitis in mice by repeated supramaximal secretagogue stimulation with caerulein. Some animals were pre-treated with the cathepsin B inhibitor CA-074me to inhibit cathepsin B, prevent intrapancreatic activation of digestive zymogens, and reduce the severity of pancreatitis. We show that inhibition of cathepsin B by pre-treatment with CA-074me prevents intrapancreatic zymogen activation and reduces organellar fragility but it does not alter the caerulein-induced colocalization phenomenon or sub-cellular F-actin redistribution or prevent caeruleininduced activation of NF-B, ERK 1/2, and JNK, or up-regulated expression of cytochemokines. We conclude (a) that the co-localization phenomenon, F-actin redistribution, activation of pro-inflammatory transcription factors, and up-regulated expression of cyto-chemokines are not the result of zymogen activation, and (b) that these early events in pancreatitis are not dependent upon cathepsin B activity. In contrast, zymogen activation and increased sub-cellular organellar fragility during caeruleininduced pancreatitis are dependent upon cathepsin B activity.
INTRODUCTION
Studies designed to elucidate mechanisms involved in the pathophysiology of acute pancreatitis should ideally be performed using clinically derived material but, unfortunately, that approach is not feasible because patients with acute pancreatitis are generally not identified during the earliest stages of the disease and, even if identified, access to the pancreas in patients with early acute pancreatitis is generally not possible.
As an alternative, most studies dealing with the events associated with early pancreatitis have been performed using animal models of the disease and the secretagogue (i.e. caerulein)-induced rodent model of acute pancreatitis is, perhaps, the most commonly employed and best characterized of those models. We have used it extensively in studies designed to elucidate mechanisms responsible for the early events in pancreatitis. In those studies, we have noted that (a) lysosomal hydrolases become co-localized with digestive enzyme zymogens (15, 25) and (b) digestive zymogens become activated within acinar cells during the very early stages of pancreatitis (21) . Similar events occur in each of the other pancreatitis models as well (8, 9, 17) . Based on these as well as other observations, we hypothesized that lysosomal hydrolases catalytically activate trypsinogen during pancreatitis and we suggested that this intra-acinar cell zymogen activation is the cause of the acinar cell injury/necrosis which leads to acute pancreatitis. Support for our hypothesis comes from the observation that cathepsin B, a lysosomal hydrolase, can catalytically activate trypsinogen and trypsin can activate the other zymogens (4, 6, 10) . Furthermore, both pharmacological inhibition of cathepsin B and genetic deletion of cathepsin B have been shown to diminish intrapancreatic activation of digestive enzyme zymogens during pancreatitis and, under these conditions, the severity Van Acker, 4 4 of pancreatitis is reduced (7, 24) . However, our hypothesis that a direct causal relationship exists between the co-localization phenomenon, intracellular zymogen activation, and acinar cell injury has been questioned by some investigators who have suggested that the co-localization phenomenon may be the result, rather than the cause, of zymogen activation and/or cell injury (11) . Similar concerns have been raised about the potential causal relationships involving some of the other early events in pancreatitise.g. acinar cell cytoskeletal changes, increased fragility of lysosome-like organelles, and activation of pro-inflammatory events.
The currently reported studies were designed to address these mechanistic cause-effect issues and to resolve uncertainty regarding whether the co-localization phenomenon is the cause or the result of intracellular zymogen activation during pancreatitis. To this end, we took advantage of the previously reported observation that (a) effective inhibition of pancreatic cathepsin B can be achieved by intravenous administration of the cellpermeant and highly specific cathepsin B inhibitor CA-074me and (b) that, under these conditions, digestive zymogen activation and the severity of caerulein-induced pancreatitis are markedly reduced (24) . In the currently reported studies, we pretreated mice with CA-074me, induced pancreatitis by supramaximal stimulation with caerulein, and evaluated the effects of cathepsin B inhibition on the co-localization phenomenon and other early events which occur during secretagogue-induced pancreatitis. We show that CA-074me pre-treatment does not alter the co-localization phenomenon in spite of the fact that the cathepsin B inhibitor prevents intrapancreatic trypsinogen activation and reduces the severity of pancreatitis. From these observations, we conclude that the co-localization phenomenon is not the result of either intrapancreatic zymogen activation or cell injury during caerulein-induced pancreatitis. On the other hand, we show that pretreatment with CA-074me does prevent the increase in sub-cellular organellar fragility which occurs during caerulein-induced pancreatitis and this finding leads us to suggest that that increased fragility may be the result of zymogen activation. Finally, we note that pre-treatment with CA-074me does not prevent F-actin redistribution, proinflammatory transcription activation, or the generation of pro-inflammatory mediators during the early stages of this pancreatitis model and these findings lead us to conclude (a) that these latter events are triggered by mechanisms that do not require either cathepsin B activity or intra-acinar cell activation of zymogens and (b) that these events may not be sufficient to induce pancreatitis in the absence of zymogen activation.
MATERIALS AND METHODS
All experiments were performed according to protocols approved by the Institutional Animal Care and Use Committee of the Tufts-New England Medical Center and C57BL/6 mice, weighing 20-25 g, obtained from Taconic (Germantown, NY), were used in these studies. The animals were housed in temperature-controlled (23 +/-2 0 C) rooms with a 12:12h light-dark cycle. They were fed standard laboratory chow, given water ad libitum, fasted overnight before each experiment, and randomly assigned to control or experimental groups. Caerulein was purchased from Sigma-Aldrich (St. Louis, MO).
The trypsin substrate (Boc-Glu-Ala-Arg-4-methylcoumaryl-7-amide, MCA) and the cell 
Induction of pancreatitis.
Mice were given caerulein (50 µg/kg body weight) by intraperitoneal injection at hourly intervals and sacrificed at selected times thereafter. Some animals were pretreated with CA-074me 1 hour before the start of caerulein administration. For this purpose, stock solutions of CA-074me (10 mg/ml) in dimethyl sulfoxide (DMSO) were prepared. The CA-074me/DMSO solution was diluted in phosphate-buffered saline (PBS) (1:10) and administered by tail-vein injection at a dose of 10mg/kg body weight. Control animals received a comparable injection of DMSO diluted in PBS.
Subcellular fractionation
At the time of sacrifice, a portion of the pancreas was homogenized in cold (4 0 C) buffer (250 mM sucrose, 5 mM [N-morpholino]propane sulfonic acid (MOPS), 1 mM MgSO 4 , pH 6.5) using a Teflon coated homogenizer. Duplicate 1 ml aliquots of the homogenate were centrifuged (150 g, 10 min, 4 0 C) and the pellet, containing unbroken cells and debris, was discarded. A 0.75 ml aliquot of each supernatant was taken and considered to be representative of the total homogenate in later calculations. It was centrifuged (1,000 g, 10 min, 4 0 C) and the resulting pellet was considered to be the "zymogen granuleenriched" fraction. The supernatant from this centrifugation was, itself, centrifuged (12,000 g, 15 min, 4 0 C) and the pellet resulting from this centrifugation was considered to be the "lysosome-enriched" fraction. The zymogen granule-enriched and the lysosome-enriched pellets were kept on ice until later assay. Preliminary studies in untreated animals, quantitating the distribution of amylase, cathepsin B, and aryl sulphatase in fractions obtained from untreated animals, revealed that 41% of amylase content was localized to the zymogen granule-rich fraction, 11% to the lysosomeenriched fraction, and 48% to the 12,000 g supernatant which was expected to contain the endoplasmic reticulum, ribosomes, and soluble components. Thirty-two percent of cathepsin B activity was localized to the zymogen granule-rich fraction, 46% to the lysosome-enriched fraction, and 22% in the 12,000 g supernatant. Twenty-nine percent of aryl sulphatase activity was found in the zymogen granule-rich fraction, 42% in the lysosome-enriched fraction, and 29% in the 12,000g supernatant.
Biochemical assays
Aryl sulfatase activity was quantitated to allow for the tracking of lysosomal hydrolases after administration of the cathepsin B inhibitor CA-074me since, under these conditions, cathepsin B activity was below the measurable threshold. For this purpose, the zymogen granule-enriched and the lysosome-enriched pellets were resuspended in 150 µl 0.2% w/v NaCl (4 0 C) and 100 µl of this suspension was added to 900 µl of pre-warmed (37 0 C) pnitrocatechol sulfate (PNCS) buffer (111.1 mM Na-acetate (pH 5.0), 2.78 mM PNCS).
The mixture was incubated at 37 0 C for 30 minutes, after which the reaction was stopped by addition of 5 ml 1 M NaOH. Aryl sulfatase activity was then fluorometrically quantitated at 515 nm using the Bio-Rad SmartSpec 3000 spectrophotometer. Amylase activity was measured using chloro-p-nitrophenyl--D-maltotrioside (Diagnostics Chemical Limited, Oxford, CT) as the substrate (3). Trypsin activity was fluorometrically measured using the specific substrate Boc-gln-ala-arg-methoxy coumarin (MCA) (Peptides International, Louisville, KY).
Subcellular localization studies
For immunolocalization of the digestive enzyme amylase and the lysosomal membrane protein-1 (LAMP-1), portions of the pancreas were frozen in optimal cutting temperature For studies evaluating possible redistribution of sub-apical F-actin, 8 µm sections were treated with sodium borohydride (1mg/ml), blocked, stained with Alexa fluor-546 conjugated phalloidin (1U/ml), rinsed with PBS, and covered with Vectashield. The localization of F-actin was quantitated as described earlier (12) .
Sub-cellular organelle fragility
After subcellular fractionation as described above, the 1,000 g x10 min pellet (i.e. the zymogen granule-enriched fraction to which lysosomal enzymes including cathepsin B and aryl sulfatase are redistributed during pancreatitis) was resuspended in 1 ml MOPS buffer and incubated at room temperature (22 ºC) for 0-120 minutes. At selected times, the samples were centrifuged (10,000 g, 2 min), a 50 µl aliquot of the supernatant containing soluble material was taken for amylase assay, and the pellet was then resuspended for the remainder of the experiment.
Activation of ERK1/2, JNK, and NF-B
Cytoplasmic protein extracts from pancreatic fragments were prepared as described earlier (2) 
Analysis of data.
The results reported represent the mean +/-SEM of values obtained from multiple determinations in three or more experiments. The significance of changes was evaluated by using student's t-test when the data consisted of only two groups or by analysis of variance (ANOVA) when comparing three or more groups. A P value of 0.05 was considered to indicate a significant difference. In all figures, vertical bars denote the SEM and the absence of such bars indicates that the SEM is too small to illustrate.
RESULTS
We have previously shown that intravenous administration of CA-074me to mice markedly inhibits pancreatic cathepsin B activity and reduces the magnitude of acinar cell injury/necrosis, pancreatic edema, and pancreatic inflammation which occur during the early stages of caerulein-induced pancreatitis (24) . These effects of the cell permeant cathepsin B inhibitor on the severity of pancreatitis appear to be relatively specific since, under in-vitro conditions, CA-074me neither alters the pancreatic acinar cell secretory response to caerulein nor directly inhibits trypsin activity (24) . Furthermore, as shown in Fig. 1 , tail vein administration of CA-074me, 1 hour prior to the intraperitoneal injection of a supramaximally stimulating dose of caerulein, markedly inhibits caerulein-induced intrapancreatic activation of trypsinogen. Based on these preliminary observations, we concluded that CA-074me might be an ideal tool for studies designed to determine whether early events in experimental pancreatitis are dependent upon prior cathepsin Binduced trypsinogen activation.
Effects of CA-074me on the "co-localization phenomenon"
Previously reported studies by our group as well as others have shown that digestive enzyme zymogens become co-localized with lysosomal hydrolases during the early stages of virtually all experimental models of pancreatitis evaluated to date (8, 9, 13-17, 25, 27) . This so-called co-localization phenomenon can be detected using either techniques of sub-cellular fractionation or techniques of immunolocalization. In the currently reported studies, both of these complementary approaches were used to probe the effects, on this phenomenon, of inhibiting cathepsin B activity and, thus, preventing intracellular zymogen activation.
Since CA-074me is a potent cathepsin B inhibitor, our subcellular fractionation studies could not use cathepsin B activity measurements to track lysosomal enzyme localization during pancreatitis and, as an alternative to accomplish our goal, we chose to track the activity of another lysosomal enzyme -i.e. aryl sulfatase-which is not inhibited by CA074me. As shown in Fig. 2 , supramaximal stimulation with caerulein causes a time-dependent change in the relative distribution of aryl sulfatase between the lysosomeenriched and zymogen granule-enriched fractions. As expected, most of the sedimentable aryl sulfatase activity is initially detected within the lysosome-enriched fraction but, with time, aryl sulfatase becomes redistributed following caerulein administration. As a result, progressively more aryl sulfatase is detected within the zymogen granule-enriched fraction while less remains in the lysosome-enriched fraction and the lysosome/zymogen granule ratio of aryl sulfatase activity falls (Fig. 2 ). This change in the distribution of aryl sulfatase activity mimics the change noted when cathepsin B distribution is monitored during the early stages of caerulein-induced pancreatitis and, from this observation, we conclude that aryl sulfatase activity can be used as a surrogate for cathepsin B activity in studies tracking the distribution of lysosomal hydrolases in the presence of a cathepsin B inhibitor such as CA-074me.
In experiments designed to achieve that goal (Fig. 2) , we find that tail vein administration of CA-074me 1 hour before the intraperitoneal injection of caerulein does not alter either the magnitude or the time-dependence of caerulein-induced aryl sulfatase redistribution between the lysosome-enriched and the zymogen granule enriched subcellular fractions.
To complement subcellular fractionation studies, confocal microscopic immunolocalization studies were performed using antibodies directed against the digestive enzyme amylase and the lysosomal membrane protein LAMP-1.
Representative images and quantitation of co-localized immunofluorescence are shown in does not alter the activation of JNK, ERK1/2 or NF-B but it does prevent the decrease in ERK 1/2 and JNK activation observed over the second 30 minute period (Fig. 6 ).
Effect of CA-074me on acinar cell generation of pro-inflammatory mediators
During the early stages of secretagogue-induced pancreatitis, the intrapancreatic expression of several pro-inflammatory mediators is increased. As shown in Fig. 7 , the increased expression of MCP-1 and IL-6 is not altered by prior inhibition of cathepsin B in spite of the fact that, under these conditions, intra-pancreatic activation of trypsinogen is prevented and the severity of pancreatitis is reduced (24) .
DISCUSSION
Co-localization of digestive enzyme zymogens with lysosomal hydrolases has been observed to occur during the very early stages of virtually every experimental pancreatitis model examined (8, 9, 13-17, 25, 27) . We have previously suggested that this colocalization phenomenon may play a causal role in the intra-cellular activation of digestive enzymes which occurs during pancreatitis since the lysosomal hydrolase cathepsin B can activate trypsinogen and trypsin can activate the other digestive zymogens. Others, however, have argued that, rather than being the cause of zymogen activation and cell injury, the co-localization phenomenon might be the result of zymogen activation and/or cell injury (11) . In this regard, the co-localization phenomenon could represent a protective response by facilitating the degradation, by lysosomal hydrolases, of inappropriately activated digestive enzymes within acinar cells.
To resolve this controversial issue, we have performed a series of studies in which the lysosomal hydrolase cathepsin B (and, perhaps, other lysosomal hydrolases as well) was inhibited by the intravenous administration of CA-074me. In previously published work,
we have shown that pre-treating mice with this cell permeant cathepsin B inhibitor virtually eliminates measurable pancreatic cathepsin B activity, prevents the intrapancreatic activation of trypsinogen which follows supramaximal stimulation with caerulein, and it markedly reduces the extent of pancreatic edema, pancreatic inflammation (i.e. increased pancreatic myeloperoxidase activity), and acinar cell injury/necrosis which occur during the early stages of caerulein-induced murine pancreatitis (24).
Our initial goal in the currently reported studies was to determine if preventing zymogen activation would, by itself, alter or prevent the co-localization phenomenon since, if that were the case, one might reasonably conclude that the co-localization phenomenon was, in some way, the result of zymogen activation. On the other hand, results indicating that preventing zymogen activation does not alter the co-localization phenomenon that is noted after supramaximal caerulein stimulation would lead to the unambiguous conclusion that the co-localization phenomenon is not the result of inappropriate intracellular activation of digestive enzyme zymogens during the early stages of caerulein-induced pancreatitis.
CA-074 is a potent cysteine protease inhibitor which is relatively specific for cathepsin B.
It binds irreversibly to Cys 29 of cathepsin B causing permanent inactivation of the enzyme (1). With 2-3 orders of magnitude lesser potency, it can also inhibit other lysosomal hydrolases including cathepsins H and L. As a result of its highly negative charge, CA074 is not very cell permeant but entry into target cells can be markedly improved by using the methyl ester form of the inhibitor. In its methyl ester form, CA074me is taken up by cells and it remains in the cell after de-esterification by intracellular esterases. In-vivo studies reported by others (22, 23) have, in general, employed CA074me doses of 4-80 mg/kg body weight and, in our studies, we used a dose of 10 mg/kg.
For our studies, CA-074me was administered by tail vein injection 1 hour prior to the intraperitoneal injection of caerulein.
After confirming that pre-treatment with CA-074me completely inhibits measureable intrapancreatic activation of trypsinogen during caerulein-induced pancreatitis in mice ( Fig. 1) , we embarked on a series of studies testing the effects of the cathepsin B inhibitor on the co-localization of digestive zymogens with lysosomal hydrolases. In our studies, we could not track either trypsin or cathepsin B activity for this purpose since, after pretreatment with CA-074me, the activity of both enzymes falls below the detectable threshold. As an alternative, we tracked aryl sulfatase and amylase activities in subcellular fractionation studies. To compliment our studies using the technique of subcellular fractionation, we also performed studies using the technique of immunolocalization and, for those studies, we tracked the lysosomal membrane protein LAMP-1 and the digestive enzyme amylase. As shown in Figs. 2 and 3 , the results of studies using these two independent but complementary techniques were similar. we evaluated organellar fragility by quantitating the conversion of sedimentable amylase into non-sedimentable amylase. We found that organellar fragility was increased in samples prepared from animals given caerulein but that pre-treatment of animals with CA-074me prevented that caerulein-induced increase in organellar fragility. It should be noted that this zymogen granule-enriched sub-cellular fraction is the fraction to which lysosomal hydrolases are redistributed during the co-localization process and it is the fraction in which digestive enzyme zymogens are activated during the early phases of caerulein-induced pancreatitis. It is tempting, therefore, to speculate that, in samples prepared from animals not exposed to CA-074me, the observed organellar disruption reflects the injurious effects of those activated digestive enzymes and that the rate of organellar rupture in samples obtained from animals exposed to CA-074me is reduced because these digestive enzymes are not activated after administration of the cathepsin B inhibitor.
In contrast to marked reduction in caerulein-induced organellar fragility, which was observed following pre-treatment with CA-074me, no change in caerulein-induced Factin redistribution was observed. This leads us to conclude that digestive enzyme activation does not play an important role in regulating the cytoskeletal changes in acinar cells that occur during the early stages of caerulein-induced pancreatitis.
We have also examined the effects of inhibiting cathepsin B on some of the proinflammatory events which occur during the evolution of caerulein-induced pancreatitisi.e. on the activation of JNK, ERK, and NF-B and on the up-regulated expression of IL-6 and MCP-1. In the absence of CA074-me administration, supramaximal stimulation with caerulein triggers the rapid activation of both JNK and ERK --i.e. elevated levels of p-JNK and p-ERK can be detected within 30 min of exposure to caerulein. Our finding that a similar rapid activation of both JNK and ERK is observed when caerulein is given after prior administration of CA074-me leads us to conclude that neither the inhibition of cathepsin B nor the prevention of trypsinogen activation interfere with the activation of these pro-inflammatory kinases. In the absence of CA074-me administration, p-JNK and p-ERK levels fall during the second 30 min period after caerulein administration but, following CA074-me administration, we found that p-JNK and p-ERK levels actually rose even higher. Taken together, these observation suggest that the fall in p-JNK and p-ERK levels which is observed during the second 30 min after caerulein administration might be the result of p-JNK and p-ERK degradation by activated zymogens such as trypsin and that, when that when cathepsin B inhibition prevents zymogen activation, degradation does not occur and a further increase in p-JNK and p-ERK levels is observed.
Within 30 min of caerulein administration, cytosolic levels of I B fall and nuclear levels of the p65 NF-B subunit rise. These changes occur regardless of whether cathepsin B has been inhibited by pre-treatment with CA-074me, a finding which leads us to suspect that NF-B activation is not dependent upon either the presence of cathepsin B activity or intrapancreatic activation of zymogens such as trypsinogen. On the other hand, our finding that the rise in nuclear levels of p65, while still significant, is somewhat attenuated after administration of CA074-me leaves open the possibility that cathepsin B
and/or activated zymogens may play contributory roles in processes involved in NF-B activation. Further studies will be needed to resolve these uncertainties. 
